DOI: 10.4274/jcrpe.galenos.2024.2024-1-3

Research Article

Comprehensive Insights into Pediatric Craniopharyngioma: Endocrine and Metabolic Profiles, Treatment Challenges, and Long-term Outcomes with a Multicenter Approach

Zeynep Şıklar[1], Elif Özsu[1], Sirmen Kızılcan Çetin[1], Samim Özen[2], Filiz Çizmecioğlu-Jones[3], Hanife Gül Balkı[2], Zehra Aycan[1], Damla Goksen[2], Fatih Kilci[3], Sema Nilay Abseyi[1], Ummahan Tercan[4], Gözde Gürpınar[3], Şükran Poyrazoğlu[4], Feyza Darendeliler[4], Korcan Demir[5], Özge Besci[5], İlker Tolga Özgen[6], Semra Bahar Akın[6], Zümrüt Kocabey Sütçü[7], Emel Hatun Aykaç Kaplan[7], Emine Çamtosun[8], İsmail Dundar[8], Elif Sağsak[9], Hüseyin Anıl Korkmaz[10], Ahmet Anık[11], Gül Yeşiltepe Mutlu[12], Bahar Özcabi[13], Ahmet Uçar[14], Aydilek Dağdeviren Çakır[14], Beray Selver Eklioğlu[15] Birgül Kırel[16], and Merih Berberoğu[1]
[1]Ankara University Faculty of Medicine, Department of Pediatric Endocrinology, Ankara, Turkey
[2]Ege University Faculty of Medicine, Department of Pediatric Endocrinology, Izmir, Turkey
[3]Kocaeli University Faculty of Medicine, Division of Pediatric Endocrinology, Kocaeli, Turkey
[4]Istanbul University Faculty of Medicine, Division of Pediatrics Endocrinology, Istanbul, Turkey
[5]Dokuz Eylül University Faculty of Medicine, Division of Pediatric Endocrinology, Izmir, Turkey
[6]Bezmialem Vakif University Faculty of Medicine, Division of Pediatric Endocrinology, Istanbul, Turkey
[7]Basaksehir Çam and Sakura City Hospital, Pediatric Endocrinology, Istanbul, Turkey
[8]İnönü University Faculty of Medicine, Department of Pediatric Endocrinology, Malatya, Turkey
[9]University of Yeditepe Faculty of Medicine, Division of Pediatric Endocrinology, Istanbul, Turkey
[10]Balıkesir Atatürk State Hospital, Division of Pediatric Endocrinology, Balıkesir, Turkey
[11]Aydın Adnan Menderes University Faculty of Medicine, Division of Pediatric Endocrinology, Aydın, Turkey
[12]Koç University Faculty of Medicine, Division of Pediatrics Endocrinology, Istanbul, Turkey
[13]Acibadem Atasehir Hospital, Division of Pediatric Endocrinology, Istanbul, Türkiye
[14]University of Health Sciences, Şişli Hamidiye Etfal Health Practices and Research Centre, Division of Pediatric Endocrinology, Istanbul, Turkey
[15]Necmettin Erbakan University Faculty of Medicine, Department of Pediatric Endocrinology, Konya, Turkey
[16] Eskisehir Osmangazi University Faculty of Medicine, Division of Pediatric Endocrinology, Eskisehir, Turkiye

What is already known about this topic?

- Craniopharyngiomas (CPG) have challenges in treatment due to their proximity to vital structures, and the tendency for recurrence.
- The pituitary axis is frequently affected during the presentation of CPG.

What this study adds to the literature?

- Recurrence of CPG was predominantly related to incomplete resection and the low rate of postoperative radiotherapy.
- The study revealed hesitancy among physicians regarding recombinant growth hormone, highlighting a need for further exploration and understanding.

Abstract

Introduction: Craniopharyngiomas (CPG) have complex challenges in treatment due to their proximity to vital structures, surgical and radiotherapeutic complexities, and the tendency for recurrence. This study aims to identify the prevalence of endocrine and metabolic comorbidities observed during initial diagnosis and long-term follow-up in a nationwide cohort of pediatric CPG patients. The study also highlights the associated difficulties in their management.

Methods: Sixteen centers entered 152 patients into the ÇEDD NET data system. We evaluated the clinical and laboratory characteristics at presentation, administered treatments, accompanying endocrine, metabolic, and other system involvements, and the patient's follow-up features.

Results: Of the evaluated patients, 64 were female, and 88 were male. At presentation, the mean age was 9.1 ± 3.67 (min:1.46-max:16.92) years. The most common complaints at presentation were headache (68.4%), vision problems (42%), short stature (15%), nausea and vomiting (7%). The surgical procedure applied to the patients was gross total resection (GTR) in 97 cases (63.8%) and subtotal resection in 55 cases (36.2%). Radiotherapy was initiated in 11.8% of the patients. In the pathological examination, 92% of the cases were adamantinamatous type, 8% were papillary type. Postoperatively, hormone deficiencies consisted of thyroid-stimulating hormone (92.1%), adrenocorticotropic hormone (81%), antidiuretic hormone (79%), growth hormone (65.1%), and gonadotropin (43.4%) deficiencies. Recombinant growth hormone treatment (rhGH) was initiated on 27 patients. The study showed hesitancy among physicians regarding rhGH. The median survival without relapse was 2.2 years. Median time of relapse was 1.82 years (range: 0.13-10.35 years). Relapse was related to longer follow-ups and reduced GTR rates. The median follow-up time was 3.13 years. Among the last follow-up visits, the prevalence of obesity was 38%, but of these, 46.5% were already obese at diagnosis. However, 20% who were not obese at baseline became obese on follow-up.

Permanent visual impairment was observed in 26 patients, neurological deficits in 13 patients, and diabetes mellitus in 5 patients.

Conclusion: Recurrence was predominantly due to incomplete resection and the low rate of postoperative radiotherapy. It also emphasized challenges in multidisciplinary regular follow ups and suggested early interventions such as dietary restrictions and increased exercise to prevent obesity.

Keywords: Craniopharyngioma, pituitary, dysfunction

Sirmen Kizilcan Cetin, MD, Department of Pediatric Endocrinology, School Of Medicine, Ankara University, Balkiraz, No:6, PC06620, Mamak, Ankara, Turkey
+903125956635
drsrmnkzlcn@gmail.com
0000-0001-7397-3071

02.01.2024
23.03.2024

Published: 25.04.2024

Introduction

One of the most difficult brain tumors to treat is a craniopharyngioma (CPG), which is characterized by benign histology but has the potential to cause serious functional and clinical issues because of where it is located in the central nervous system. It frequently involves the sellar and suprasellar regions, compressing nearby tissues (1-5). The complex nature of its surgical management, compounded by its complicated anatomical positioning, has encouraged the exploration of novel treatment strategies. In contrast to treatment techniques, follow-up data show no appreciable differences in long-term effects (1, 6, 7). It constitutes 1.2-10% of all pediatric brain tumors, with an incidence of 0.5-2.5 cases per 1,000,000 individuals, making it particularly prevalent in the pediatric population (1, 2). It is most commonly diagnosed in children. It exhibits a two-peak age distribution, with the highest occurrences observed in individuals aged 5 to 15 years during childhood and another peak in individuals aged 45 to 60 years in adulthood (2, 3).

Endocrine disorders in patients with CPG significantly affect their quality of life (4-12). The pituitary axis is frequently affected during the presentation (2, 3, 13, 14). Furthermore, radiotherapy impacts hypothalamic-pituitary function (3, 6, 15-18). Compared to the pituitary gland, the hypothalamus is more susceptible to damage by radiation (16, 17). Because hypothalamic function is impaired, 40–50% of patients are affected by hypothalamic obesity (7, 14, 19-21). Moreover, the degree of hypothalamic involvement before surgical intervention holds significance in determining the enduring results of the surgical procedure (21-23).

Interventions and treatments for endocrine and metabolic problems also present challenges. Although replacement therapy for pituitary hormones is stated not to cause a risk for CPG recurrence, it remains controversial (24-27). The effect of recombinant human growth hormone on the psychosocial status and quality of life has been investigated, and it has been shown that individuals who take rhGH during the growth period have better height growth; however, this did not lead to weight loss in adult patients except for the pediatric group (27-29). Managing pediatric CPG is challenging due to the complex diagnostic process, the distinctiveness of their anatomical positions, the extent of involvement in surrounding tissues, the secondary harm induced by treatments, the weight of endocrine and metabolic complications, and the adverse impacts on sustained quality of life. The aim of this research is twofold: first, to determine the prevalence of endocrine and metabolic comorbidities during the diagnostic phase and long-term follow-up in a national cohort of pediatric patients diagnosed with CPG; second, to determine the problems involved in successfully treating the endocrine issues in these situations.

Method:

Clinical and laboratory enrollment criteria

This investigation aimed to comprehensively assess individuals under follow-up at Pediatric Endocrinology centers who were experienced with CPG management. The study involved the active participation of 16 different endocrinology departments. Patients' data entry into the CEDD-NET database was uploaded through cooperative efforts of participating centers to enhance data gathering for this study. The investigation of several aspects, such as the age at which the disease first manifested, clinical manifestation, length of symptoms, demographic traits, MRI results at diagnosis, surgical and/or radiotherapy treatments used, and tumor histology, was covered by the study protocol.

Comprehensive datasets capturing concurrent endocrine, metabolic, ophthalmologic, and neurological profiles were systematically collected. The physical evaluation included height standard deviation score (SDS), visual acuity (VA) assessment, BMI, and Tanner's puberty stage. Additionally, laboratory investigations, including thyroid function (TSH, fT4), adrenal function (ACTH, cortisol), prolactin levels, gonadotropins, testosterone/estradiol levels, and, in instances of growth hormone (GH) deficiency, insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding protein 3 (IGFBP3) levels, were assessed. Central Diabetes Insipidus (CDI) presence and treatments were also evaluated. Quantitative measures of fasting insulin levels, lipid profiles, aspartate aminotransferase (AST) and alanine transaminase (ALT) levels, and uric acid concentrations were required to evaluate metabolic health.

The patients underwent a thorough ophthalmologic and neurological examination and assessments of any associated social and psychiatric issues, cardiovascular symptoms, obstructive sleep apnea, and further symptomatic presentations. The complexities of post-diagnostic monitoring were investigated, including the typical follow-up time, the resulting magnetic resonance imaging (MRI) results, and disparities observed in the endocrine, metabolic, ophthalmologic, and neurological systems. Reoperations that followed tumor recurrences were documented.

Inclusion criteria required participants to have received a definitive diagnosis below 18 years, substantiated by unequivocal pathological confirmation of CPG. Conversely, candidates were excluded if their diagnosis rested solely on clinical and radiological grounds, lacking pathological confirmation.

The Local Ethics Committee approved the study by approval number I2-130-21.

Results:

Study Participants and Clinical Presentation:

One hundred fifty-two patients (64 females and 88 males) were enrolled in the study. At the time of diagnosis, the mean age was 9.1 years. The height SDS was -1.09±1.5, and the BMI SDS was 0.7±1.6 The study included 110 prepubertal and 42 pubertal patients. Notably, 39 (25%) patients had short stature at diagnosis. Distribution was as follows: 19 girls had a height SD of -2.9±0.14 SD and 20 boys had a height SD of -3.1±0.20 SD. Additionally, at the point of diagnosis, 35 (23% patients were classified as obese, including 10 girls (BMI SD: 2.6±0.16 SD) and 25 boys (BMI SD: 2.7±0.15 SD) (Table 1).

Of the 152 patients, the foremost initial complaint was headache (68.4%). Sixty-five patients (42%) had vision problems (52 patients experiencing reduced VA, 7 had restricted field of vision, 2 presenting diplopia, and 2 exhibiting nystagmus). Other presenting complaints included obesity in 38 patients (25%), impaired growth in 23 patients (15%), nausea and vomiting in 11 patients (7%), neurological symptoms (seizure, drowsiness, ataxia, tremor) in 14 patients (9%) and pubertal problems in 4 patients (3%) (Table 1).

In the first evaluation, hormone deficiencies were observed in descending order: TSH deficiency in 121 patients (79%), ACTH deficiency in 106 patients (69%), CDI in 95 patients (62.5%), GH deficiency in 83 patients (54.6%), gonadotropin deficiency in 63 patients (41%). Totally 137 patients had prolactin (PRL) measurements. Of these, 48 patients had elevated PRL levels, 68 patients had normal and 23 patients had low PRL levels (Table 1).

Cranial Imaging and Extension Patterns:

Cranial imaging showed that extension into a single area was observed in 64 patients, with 55 involving the suprasellar region, 5 of the third ventricle, 4 of the anterior fossa (one each for infundibulum, optic chiasm, and other parts). Extension into multiple areas was noted in 43 patients. Thirteen patients showed no extension, while 32 patients had unspecified extension patterns.

Treatment Approaches and Outcomes: Transnasal interventions were performed on 76 patients (50%), endoscopic procedures on 73 patients (48%), and gamma knife treatment on two patients (1.3%). The type of operation was not specified in one patient. Notably, 73 patients (48%)

underwent triple-phase interventions., which consisted of the first stage of transient CDI, second stage of an antidiuretic phase, and the permanent CDI phase (30, 31). Radiotherapy was initiated in 11.8% of the patients.

Pathology and Tumor Characteristics:

The pathological evaluation of 46 patients was not stated in the study. Among the 106 patients, 92% were classified as the adamantinomatous type, while 8% exhibited the papillary type. The mean tumor diameter measured was 3.7±1.5 cm.

Postoperative Complications and Findings: The mean follow-up duration was 4.5 ±3.9 years. At the last follow-up, the mean age was 13.7±49 years, with the height SDS documented as -1.1±1.62. Among the patients, 36 (23.6%) had a height SDS below -2SD (Table 2). Relapse was observed in 56 patients (38%), with a median time of 1.82 years (range: 0.13-10.35 years). No significant differences in age, gender, or tumor size were observed between patients with and without relapse ($p>0.05$). The follow-up duration was 5.4± 3.6 years for patients with relapse and 3.83 years for those without. Complete resection was achieved in 57% of patients with relapse and 71% in those without. The significant factors contributing to the development of relapses were the inability to achieve complete resection and the low rate of adding postoperative RT.

Hormone Deficiencies and Outcomes: Hormone deficiencies were prevalent at the final assessment: TSH deficiency in 140 patients (92.1%), ACTH deficiency in 123 patients (81%), CDI in 120 patients (78.1%), GH deficiency in 99 patients (65.1%), and gonadotropin deficiency in 66 patients (43.4%) (Table 2).

Among the preoperative patients, 35 individuals (23%) were obese, and 58 individuals (38 %) were obese in the postoperative period. However, 20% who were not obese at baseline became obese on follow-up. In the postoperative period, 31 new obese patients were added. Eight of 35 patients, that were preoperatively obese, had normal BMI in the postoperative follow-up .

Among the patients, 12 /42 (28%) had a metabolic status indicating prediabetes and 4 /120 (3%) had diabetes mellitus. On follow-up, neurological deficits were observed in 13 patients, accounting for 8.6% of the patients. Among these, five patients experienced epilepsy, while three had motor deficits.

There was no significant difference in survival between relapse and nonrelapse groups. However, due to the limited number of patients, statistical significance could not be demonstrated.

Discussion

Craniopharyngioma constitutes a significant portion of childhood central nervous system tumors (1, 2). Our patients had a mean age of diagnosis around 9.2 years. According to Beckhaus et al., CP patients with a younger age at diagnosis (less than 12 years old) had a worse event-free survival rate(21). Our contribution could enhance this interpretation, particularly considering the long-term follow-up encompassing adult age. The literature suggests that the most common clinical manifestations include headaches, visual impairment, and endocrine issues (growth retardation, obesity, delayed puberty, CDI) (5, 13, 22, 23, 32-34). Approximately 60–75% of patients primarily report headaches; similar to ours, headaches were the most common presenting complaint (68.4%)(32). During initial evaluations, 70-80% of patients may have visual impairments (32). A notable 42% of our patients experienced visual disturbances as their first symptom. However, this occurrence might differ based on the tumor's location in the chiasm (anterior or posterior) and the tumor's asymmetric extension in our study. Among patients afflicted by suprasellar CPGs, 50% exhibited decreased visual acuity and visual field impairment at diagnosis. Interestingly, existing literature indicated a prevalence of 38% during the diagnostic phase, which further diminished to 15% postoperatively. These findings underscore the similarity of results (35).

During the diagnostic phase, hormonal imbalances were described in 93% of the patients. Studies highlighted that hormonal involvement was evident in 40% to 87% of patients during their diagnostic assessment (34). Our findings were at the upper end of the range. This situation might be attributed to the age at diagnosis and the specific region affected by the tumor.

In the literature, approximately 26% to 75% of CPG patients are reported to have growth hormone deficiency at the time of diagnosis, which increases to around 70% to 92% postoperatively. Our study is compatible with these findings, suggesting a correlation with the limited preoperative endocrinological assessment. Without preoperative multidisciplinary assessment, clinicians might have been included in the postoperative process. In this scenario, a comprehensive examination could not be provided at the time of diagnosis. In a study by Muller et al., preoperative GH deficiency was observed in 83 patients (54%), while postoperative growth hormone deficiency was noted in 99 patients (65.1%). Among them, 28 patients (18%) were initiated on rhGH(36). Similar to other studies in the literature, the most frequently reported hormone deficiency in our study was TSH deficiency (4, 32).

In our study, the majority of patients displayed permanent hypopituitarism symptoms. In the literature, postoperative hypopituitarism was reported at a rate of 57-98%. Permanent CDI was reported in 64-80%. Endocrine disorders frequently observed during diagnosis and follow-up in CPG patients significantly contribute to reduced quality of life (4-12).

Sklar et al.(36) reported GH deficiency in 75% of patients, gonadotropin deficiency in 40%, TSH in 25%, and ACTH in 25%. They also indicated CDI in the 9-17% (postoperative: 40-80%)(34). Caldarelli et al. found GH deficiency in 82%, ACTH deficiency in 76%, TSH deficiency in 73%, and gonadotropin deficiency in 67% of patients (37). In our patients, tumor extension was predominantly suprasellar, consistent with the literature (38). The impact of the tumor, surgical intervention, and RT are significant factors contributing to hypopituitarism.

Although rarely malignant, CPG presents difficulties in treatment due to its proximity to vital structures, incomplete resection, and tendency to recur. Furthermore, delayed diagnosis is common in children. If complete removal is not possible, subtotal resection with radiotherapy for residual tumors is necessary. There is no consensus on the ideal surgical approach (3, 4, 13, 14, 21, 22, 39). Aggressive gross total resection (GTR), previously more commonly practiced, is now associated with higher endocrine problems and decreased quality of life. Subtotal removal with preservation of the pituitary and cranial nerves, followed by radiation, has become more preferred. Long-term quality of life data after endoscopic endonasal surgery is limited (4, 5, 13, 14, 21, 23, 32, 39, 40). In our study, GTR was achievable in most patients (n=97, %63.8). Despite the benign nature of CPGs, it has the potential for relapse. There are no guidelines on managing pediatric CPGs regarding the ideal surgical approach (3, 4, 13, 14, 21, 22, 39). Surgical procedures might differ based on the utilization of a personalized approach. Transnasal intervention was the most frequently performed in our patient group. However, due to tumor size, vital organ proximity, and unsuitable location, complete resection was not feasible for all subjects. In the literature, the likelihood of recurrence is more remarkable in pediatric patients than in adults due to the adamantinomatous variant. GTR might not exterminate recurrence risk (22, 41, 42). Literature suggests variable disease control, with recurrence rates reported at 36.4%-40% after GTR(41, 43). Despite the prevailing notion that GTR tends to prevent a recurrence, the likelihood of hypothalamic/pituitary damage affects quality of life, and some researchers advocate the benefits of conservative treatments (4).

Following surgery, the number of patients undergoing triphasic response of pituitary stalk injury leading to CDI development reached 73 (48%). In the pediatric age group, a higher number of patients undergo triple-phase interventions compared to adults(2). This seems to be associated with tumor size and the damage inflicted on surrounding tissues by surgery.

Pathologically, most of the patients in the study were diagnosed with adamantinomatous type CPG in our research. It is the most common histological subtype of CPG and exhibits a bimodal age distribution, with the highest incidence occurring in children aged 5–15 years and adults aged 45–60 (2). Pediatric CPG, which predominately manifests as the adamantinomatous subtype, differs in pathology and genetic characteristics from adults. The underlying molecular and cellular mechanisms for the adamantinomatous type involve mutations in the

CTNNB1 gene, responsible for encoding β-catenin. On the other hand, papillary CPGs in adults are associated with BRAF V600E mutations. The pathological and genetic characteristics could also affect recurrence outcomes, hormonal imbalances, and survival (2, 32). While the papillary type is observed at a low frequency, cases occurring during childhood have also been reported in the literature(44, 45). This situation is elucidated more clearly through the identification of underlying molecular mechanisms. However, due to the retrospective nature of our study, molecular assessment could not be assessed.

Eighteen patients had received postoperative RT. There was no significant difference in survival compared to other patient groups. However, due to the limited number of patients, statistical significance could not be demonstrated. A recent meta-analysis suggests that GTR and STR, along with RT, exhibit similar survival outcomes for CPG; due to the small sample size in our study, statistical confirmation could not be assessed (45).

On follow-up, neurological deficits were observed in 13 patients, accounting for 8.6% of the patients. Among these, five patients experienced epilepsy, while three had motor deficits. The reported rates of neurological complications in the previous series ranged from 8% to 36%, aligning well with our findings (10).

In CPG, hypothalamic obesity is challenging, leading to metabolic problems and being unresponsive to lifestyle changes.Hypothalamic findings may be disregarded during the follow-up. It is known that preoperative hypothalamic engagement and hypothalamic damage during operation lead to preoperative and postoperative obesity (2, 46). In individuals affected by hypothalamic damage, there is a decrease in energy expenditure, an increase in daytime sleepiness, and a disrupted response in signals related to leptin, ghrelin, and insulin. As a consequence, hyperinsulinemia develops (47). Obesity developed in 31 patients during follow-up. At diagnosis, 35 patients (23%) were obese. Among the postoperative patients, 58 patients (38%) were obese, of which 27 (18%) were already obese at the time of initial presentation. In the literature, the prevalence of obese patients at diagnosis ranges from 12% to 19%. Furthermore, it has been reported that the frequency of severe obesity after six months postoperatively is approximately 55% (10). Similar to the literature, half of the patients exhibited obesity (48). Notably, lifestyle modifications and other traditional treatments for obesity typically fail to control the condition(2, 46). Medical treatment options such as triiodothyronine, octreotide, dextroamphetamine, methylphenidate, sibutramine, and GLP-1 receptor agonists lacked generally applicable scientific evidence and showed side effects(46). Obesity surgery can not achieve permanent weight loss and also causes malabsorption of oral hormone replacement medications(46). Unfortunately, there is no definitive treatment option for hypothalamic obesity. rhGH replacement improves growth, weight, and neuropsychology in the pediatric population receiving rhGH treatment (24-27). In our study, the utilization of rhGH appears to be less widespread than recommended to control metabolic parameters (25, 46). The study showed hesitancy among physicians regarding rhGH. It might be delayed due to the risk of side effects. However, rhGH replacement therapy does not adversely affect disease-free survival(25, 46, 49, 50). It is significant that rhGH treatment should not be delayed in these patients with CPG.

This study has some limitations attributed to the retrospective design of the study and the lack of homogeneity in data collection. Specifically, hypothalamic syndrome data could not be obtained from all participating centers. The onset of obesity could not be assessed for the initial year. Moreover, there is a deficiency in the detailed features of cranial imaging.

In conclusion, CPG is a complicated issue within the pediatric age group, requiring a comprehensive approach. Challenges in multidisciplinary regular follow-ups have been identified, and it is suggested that early interventions involving calorie restriction and increased exercise for obesity should be considered. The components of Hypothalamic Syndrome (including eating disorders, circadian sleep changes, temperature variations, and heart rate variability) should be taken into consideration during patient follow-ups. Recurrence was predominantly due to incomplete resection and the low rate of postoperative radiotherapy.

Statements

Statement of Ethics

Written informed consent was obtained from the patients and parents for publication of this study. The Local Ethics Committee approved the study by approval number I2-130-21.

Conflict of Interest Statement

The authors have no conflicts of interest to declare.

Funding Sources

This case report was not supported by any sponsor or funder.

Author Contributions

Medical Practices:ZS, EO, SKC, SO, FCJ, HB, ZA, DG, FK, SNA, UT, GG, SP, FD, KD, OB, ITO, SBA, ZKS, EHAK, EC, ES, HAK, AA, GYM, BO, AU, ADC,BSE, BK, MB Concept:ZS, MB, Design: ZS, MB, Data collection: ZS, EO, SKC, SO, FCJ, HB, ZA, DG, FK, SNA, UT, GG, SP, FD, KD, OB, ITO, SBA, ZKS, EHAK, EC, ES, HAK, AA, GYM, BO, AU, ADC,BSE, BK, MB, Analysis: : ZS, SKC, EO, MB, Literature Search: ZS, SKC, EO, Writing: ZS, SKC, EO, MB

Data Availability Statement

Data sharing is not applicable.

References

1. Asirvatham JR, Deepti AN, Chyne R, Prasad MS, Chacko AG, Rajshekhar V, et al. Pediatric tumors of the central nervous system: a retrospective study of 1,043 cases from a tertiary care center in South India. Childs Nerv Syst. 2011;27(8):1257-63.
2. Müller HL, Merchant TE, Warmuth-Metz M, Martinez-Barbera JP, Puget S. Craniopharyngioma. Nat Rev Dis Primers. 2019;5(1):75.
3. Müller HL, Merchant TE, Puget S, Martinez-Barbera JP. New outlook on the diagnosis, treatment and follow-up of childhood-onset craniopharyngioma. Nat Rev Endocrinol. 2017;13(5):299-312.
4. Enayet AER, Atteya MME, Taha H, Zaghloul MS, Refaat A, Maher E, et al. Management of pediatric craniopharyngioma: 10-year experience from high-flow center. Childs Nerv Syst. 2021;37(2):391-401.
5. Lim MJR, Wee RGM, Aw NMY, Liu SJ, Ho CWL, Teo K, et al. Management and Outcomes of Pediatric Craniopharyngioma: A 15-Year Experience in Singapore. World Neurosurgery. 2023.
6. Merchant TE, Dangda S, Hoehn ME, Wu S, Li Y, Wang F, et al. Pediatric Craniopharyngioma: The Effect of Visual Deficits and Hormone Deficiencies on Long-Term Cognitive Outcomes After Conformal Photon Radiation Therapy. International Journal of Radiation Oncology* Biology* Physics. 2023;115(3):581-91.
7. van Santen SS, Olsson DS, Hammarstrand C, Wijnen M, Fiocco M, van den Heuvel-Eibrink MM, et al. Body Composition and Bone Mineral Density in Craniopharyngioma Patients: A Longitudinal Study Over 10 Years. J Clin Endocrinol Metab. 2020;105(12).
8. Yano S, Kudo M, Hide T, Shinojima N, Makino K, Nakamura H, et al. Quality of Life and Clinical Features of Long-Term Survivors Surgically Treated for Pediatric Craniopharyngioma. World Neurosurg. 2016;85:153-62.
9. Kendall-Taylor P, Jönsson PJ, Abs R, Erfurth EM, Koltowska-Häggström M, Price DA, et al. The clinical, metabolic and endocrine features and the quality of life in adults with childhood-onset craniopharyngioma compared with adult-onset craniopharyngioma. Eur J Endocrinol. 2005;152(4):557-67.

10. Poretti A, Grotzer MA, Ribi K, Schönle E, Boltshauser E. Outcome of craniopharyngioma in children: long-term complications and quality of life. Dev Med Child Neurol. 2004;46(4):220-9.
11. Müller HL, Bruhnken G, Emser A, Faldum A, Etavard-Gorris N, Gebhardt U, et al. Longitudinal study on quality of life in 102 survivors of childhood craniopharyngioma. Childs Nerv Syst. 2005;21(11):975-80.
12. Dekkers OM, Biermasz NR, Smit JW, Groot LE, Roelfsema F, Romijn JA, et al. Quality of life in treated adult craniopharyngioma patients. Eur J Endocrinol. 2006;154(3):483-9.
13. Müller HL. Childhood craniopharyngioma--current concepts in diagnosis, therapy and follow-up. Nat Rev Endocrinol. 2010;6(11):609-18.
14. Müller HL. The Diagnosis and Treatment of Craniopharyngioma. Neuroendocrinology. 2020;110(9-10):753-66.
15. Merchant TE, Hua CH, Shukla H, Ying X, Nill S, Oelfke U. Proton versus photon radiotherapy for common pediatric brain tumors: comparison of models of dose characteristics and their relationship to cognitive function. Pediatr Blood Cancer. 2008;51(1):110-7.
16. Appelman-Dijkstra NM, Kokshoorn NE, Dekkers OM, Neelis KJ, Biermasz NR, Romijn JA, et al. Pituitary Dysfunction in Adult Patients after Cranial Radiotherapy: Systematic Review and Meta-Analysis. The Journal of Clinical Endocrinology & Metabolism. 2011;96(8):2330-40.
17. Follin C, Erfurth EM. Long-Term Effect of Cranial Radiotherapy on Pituitary-Hypothalamus Area in Childhood Acute Lymphoblastic Leukemia Survivors. Curr Treat Options Oncol. 2016;17(9):50.
18. Graffeo CS, Perry A, Link MJ, Daniels DJ. Pediatric Craniopharyngiomas: A Primer for the Skull Base Surgeon. J Neurol Surg B Skull Base. 2018;79(1):65-80.
19. van Santen SS, Olsson DS, Hammarstrand C, Wijnen M, van den Heuvel-Eibrink MM, van der Lely AJ, et al. Diagnosing metabolic syndrome in craniopharyngioma patients: body composition versus BMI. Eur J Endocrinol. 2019;181(2):173-83.
20. Lustig RH. Hypothalamic obesity after craniopharyngioma: mechanisms, diagnosis, and treatment. Frontiers in endocrinology. 2011;2:60.
21. Beckhaus J, Friedrich C, Boekhoff S, Calaminus G, Bison B, Eveslage M, et al. Outcome after pediatric craniopharyngioma: the role of age at diagnosis and hypothalamic damage. European Journal of Endocrinology. 2023;188(3):300-9.
22. Agresta G, Campione A, Veiceschi P, Gallo D, Agosti E, Massimi L, et al. Clinical and oncological outcomes in single-stage versus staged surgery for pediatric craniopharyngiomas: a multicenter retrospective study. Journal of Endocrinological Investigation. 2023;46(6):1219-32.
23. Jazbinšek S, Kolenc D, Bošnjak R, Faganel Kotnik B, Zadravec Zaletel L, Jenko Bizjan B, et al. Prevalence of Endocrine and Metabolic Comorbidities in a National Cohort of Patients with Craniopharyngioma. Horm Res Paediatr. 2020;93(1):46-57.
24. Price DA, Jönsson P. Effect of growth hormone treatment in children with craniopharyngioma with reference to the KIGS (Kabi International Growth Study) database. Acta Paediatr Suppl. 1996;417:83-5.
25. Nguyen Quoc A, Beccaria K, González Briceño L, Pinto G, Samara-Boustani D, Stoupa A, et al. GH and Childhood-onset Craniopharyngioma: When to Initiate GH Replacement Therapy? The Journal of Clinical Endocrinology & Metabolism. 2023;108(8):1929-36.
26. Alotaibi NM, Noormohamed N, Cote DJ, Alharthi S, Doucette J, Zaidi HA, et al. Physiologic Growth Hormone-Replacement Therapy and Craniopharyngioma Recurrence in Pediatric Patients: A Meta-Analysis. World Neurosurg. 2018;109:487-96.e1.
27. Price DA, Wilton P, Jönsson P, Albertsson-Wikland K, Chatelain P, Cutfield W, et al. Efficacy and safety of growth hormone treatment in children with prior craniopharyngioma: an analysis of the Pharmacia and Upjohn International Growth Database (KIGS) from 1988 to 1996. Horm Res. 1998;49(2):91-7.
28. Boekhoff S, Bogusz A, Sterkenburg AS, Eveslage M, Müller HL. Long-term Effects of Growth Hormone Replacement Therapy in Childhood-onset Craniopharyngioma: Results of the German Craniopharyngioma Registry (HIT-Endo). Eur J Endocrinol. 2018;179(5):331-41.
29. Heinks K, Boekhoff S, Hoffmann A, Warmuth-Metz M, Eveslage M, Peng J, et al. Quality of life and growth after childhood craniopharyngioma: results of the multinational trial KRANIOPHARYNGEOM 2007. Endocrine. 2018;59(2):364-72.
30. SECKL JR, DUNGER DB, LIGHTMAN SL. Neurohypophyseal peptide function during early postoperative diabetes insipidus. Brain. 1987;110(3):737-46.
31. Hannon MJ, Finucane FM, Sherlock M, Agha A, Thompson CJ. Disorders of Water Homeostasis in Neurosurgical Patients. The Journal of Clinical Endocrinology & Metabolism. 2012;97(5):1423-33.
32. Drapeau A, Walz PC, Eide JG, Rugino AJ, Shaikhouni A, Mohyeldin A, et al. Pediatric craniopharyngioma. Childs Nerv Syst. 2019;35(11):2133-45.
33. Liu AP, Tung JY, Ku DT, Luk CW, Ling AS, Kwong DL, et al. Outcome of Chinese children with craniopharyngioma: a 20-year population-based study by the Hong Kong Pediatric Hematology/Oncology Study Group. Childs Nerv Syst. 2020;36(3):497-505.
34. Sklar CA. Craniopharyngioma: endocrine sequelae of treatment. Pediatr Neurosurg. 1994;21 Suppl 1:120-3.
35. Nuijts MA, Veldhuis N, Stegeman I, van Santen HM, Porro GL, Imhof SM, et al. Visual functions in children with craniopharyngioma at diagnosis: A systematic review. PLoS One. 2020;15(10):e0240016.
36. Müller HL, Gebhardt U, Teske C, Faldum A, Zwiener I, Warmuth-Metz M, et al. Post-operative hypothalamic lesions and obesity in childhood craniopharyngioma: results of the multinational prospective trial KRANIOPHARYNGEOM 2000 after 3-year follow-up. Eur J Endocrinol. 2011;165(1):17-24.
37. Calcagnelli M, Massimi L, Tamburrini G, Cappa M, Di Rocco C. Long-term results of the surgical treatment of craniopharyngioma: the experience at the Policlinico Gemelli, Catholic University, Rome. Childs Nerv Syst. 2005;21(8-9):747-57.
38. Hoffmann A, Brentrup A, Müller HL. First report on spinal metastasis in childhood-onset craniopharyngioma. Journal of neuro-oncology. 2016;129:193-4.
39. Müller HL. Paediatrics: surgical strategy and quality of life in craniopharyngioma. Nat Rev Endocrinol. 2013;9(8):447-9.
40. Yousuf OK, Salehani A, Zimmerman K, Estevez-Ordonez D, Madura C, Arynchyna-Smith A, et al. Does subtotal resection ameliorate hypothalamic morbidity in pediatric craniopharyngioma? A 30-year retrospective cohort study. Journal of Neurosurgery: Pediatrics. 2023;1(aop):1-7.
41. Sarkar S, Chacko SR, Korula S, Simon A, Mathai S, Chacko G, et al. Long-term outcomes following maximal safe resection in a contemporary series of childhood craniopharyngiomas. Acta Neurochir (Wien). 2021;163(2):499-509.
42. Puget S, Garnett M, Wray A, Grill J, Habrand JL, Bodaert N, et al. Pediatric craniopharyngiomas: classification and treatment according to the degree of hypothalamic involvement. J Neurosurg. 2007;106(1 Suppl):3-12.
43. Gautier A, Godbout A, Grosheny C, Tejedor I, Coudert M, Courtillot C, et al. Markers of recurrence and long-term morbidity in craniopharyngioma: a systematic analysis of 171 patients. J Clin Endocrinol Metab. 2012;97(4):1258-67.
44. Crotty TB, Scheithauer BW, Young WF, Jr., Davis DH, Shaw EG, Miller GM, et al. Papillary craniopharyngioma: a clinicopathological study of 48 cases. J Neurosurg. 1995;83(2):206-14.

45. Borrill R, Cheesman E, Stivaros S, Kamaly-Asl I, Gnanalingham K, Kilday J-P. Papillary craniopharyngioma in a 4-year-old girl with BRAF V600E mutation: a case report and review of the literature. Child's Nervous System. 2019;35:169-73.
46. Gan H-W, Morillon P, Albanese A, Aquilina K, Chandler C, Chang Y-C, et al. National UK guidelines for the management of paediatric craniopharyngioma. The Lancet Diabetes & Endocrinology. 2023.
47. Holmer H, Ekman B, Björk J, Nordstöm CH, Popovic V, Siversson A, et al. Hypothalamic involvement predicts cardiovascular risk in adults with childhood onset craniopharyngioma on long-term GH therapy. Eur J Endocrinol. 2009;161(5):671-9.
48. Wijnen M, van den Heuvel-Eibrink MM, Janssen J, Catsman-Berrevoets CE, Michiels EMC, van Veelen-Vincent MC, et al. Very long-term sequelae of craniopharyngioma. Eur J Endocrinol. 2017;176(6):755-67.
49. Losa M, Castellino L, Pagnano A, Rossini A, Mortini P, Lanzi R. Growth hormone therapy does not increase the risk of craniopharyngioma and nonfunctioning pituitary adenoma recurrence. The Journal of Clinical Endocrinology & Metabolism. 2020;105(5):1573-80.
50. Olsson DS, Buchfelder M, Wiendieck K, Kremenevskaja N, Bengtsson B, Jakobsson KE, et al. Tumour recurrence and enlargement in patients with craniopharyngioma with and without GH replacement therapy during more than 10 years of follow-up. Eur J Endocrinol. 2012;166(6):1061-8.

Table 1. Demographic Characteristics, Clinical and Laboratory Evaluation of Patients with Craniopharyngioma at Presentation

Demographic Characteristics	
Patients (n)	152
Age at the time of diagnosis (year)	9.1 ±3.6
Sex	
Female (n)	64 (42%)
Male (n)	88 (58%)
Height SDS	-1.9 ±1.5
Short stature at diagnosis	
Female (n)	19 (Height SD: -2.9±0.14)
Male (n)	20 (Height SD: -3.1±0.20)
BMI SDS	0.7 ±1.6
Obesity at diagnosis	
Female (n)	10 (BMI SD: 2.6±0.16)
Male (n)	25 (BMI SD: 2.7±0.15)
Pubertal status	
Prepubertal (n)	110 (72%)
Pubertal (n)	42 (28%)
Symptoms at Diagnosis	
Headache	104 (68%)
Had vision problems	
reduced visual acuity	52 (34%)
restricted vision	7 (5%)
diplopia	2 (1%)
nystagmus	2 (1%)
Impaired growth	23 (15%)
Nausea and vomiting	11 (7%)
Neurological symptoms	14 (9%)
Pubertal problems	4 (3%)
Hormone Deficiencies in Patients	
TSH deficiency	121 (79%)
ACTH deficiency	106 (69%)
Central Diabetes Insipidus	95 (62.5%)
GH deficiency	83 (54.6%)
Gonadotropin deficiency	63 (41%)
Prolactin level (n=137)	
▪ Elevated	48 (35%)
▪ Normal	68 (49.6%)
▪ Low	23 (16.7%)

Table 2. Postoperative Follow-up and Outcomes in Patients with Craniopharyngioma

Postoperative Findings –Follow-up	
Follow-up duration (years)	4.5 ± 3.9 [0.08 ; 20]
Age at last follow-up (years)	13.7 ± 4.9 [2.9 ; 29]
Height SDS	-1.1 ± 1.6 [-6.4 ; 2.6]
BMI SDS	1.4 ± 1.4 [-2.35 ; 5.08]
Relapse(n)	58 (38.2%)
Remission (n)	92 (60.5%)
Type of surgery	
GTR (n)	97 (63.8%)
Subtotal (n)	54 (35.5%)
Transnasal(n)	76 (50%)
Endoscopic(n)	73 (48%)
Gamma knife (n)	2 (1.3%)
Radiotherapy (n)	18 (11.8%)
Postoperative Hormone Deficiencies in Patients	
Growth Hormone deficiency	99 (65.1%)
Gonadotropin deficiency (total 109 pubertal status)	66 (43.4%)
TSH deficiency	140 (92.1%)
ACTH deficiency	123 (81%)
Central Diabetes Insipidus	120 (78.9%)